Investigational drugs in Alzheimer's disease: current progress

Bibliography

• Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22
   PubMed Web of Science ®Google Scholar
• Mirra SS, Heyman A, McKeel D, et al. The Consortium to establish a registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41(4):479-86
   PubMed Web of Science ®Google Scholar
• Atri A, Molinuevo JL, Lemming O, et al. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 2013;5(1):6
   PubMed Web of Science ®Google Scholar
• Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta- amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38(4):547-54
   PubMed Web of Science ®Google Scholar
• Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the gamma-secretase inhibitor Avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 2012;69(11):1430-40
   PubMed Web of Science ®Google Scholar
• Vellas B, Sol O, Snyder PJ, et al. EHT 0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res 2011;8(2):203-12
   PubMed Web of Science ®Google Scholar
• Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of abeta. J Neurosci 2012;32(28):9677-89
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Evaluation of the efficacy of varenicline on cognition, safety, tolerability and pharmacokinetics in subjects with mild-to-moderate Alzheimer's disease. Available from: www.ClinicalTrials.gov (Identifier NCT00744978)
   Google Scholar
• Ryan JM, Grundman M. Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. J Alzheimers Dis 2009;17(2):243
   PubMed Web of Science ®Google Scholar
• Lambracht-Washington D, Rosenberg RN. Active DNA Abeta42 vaccination as immunotherapy for Alzheimer disease. Transl Neurosci 2012;2:307-13
   Google Scholar
• AFFiRiS AG. Clinical and immunological activity, safety and tolerability of different doses/formulations of AFFITOPE AD02 in early Alzheimer's disease. Available from: www.Clinicaltrials.gov (Identifier: NCT01117818)
   Google Scholar
• Lemere CA, Masliah E. Can Alzheimer's disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010;6(2):108-19
   PubMed Web of Science ®Google Scholar
• Barone E, Di Domenico F, Butterfield DA. Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol 2013. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, Vega GL, Lutjohann D, et al. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis Assoc Disord 2010;24(3):220-6
   PubMed Web of Science ®Google Scholar
• He P, Cheng X, Staufenbiel M, et al. Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of beta-secretase in a mouse model of Alzheimer's disease. PLoS One 2013;8(2):e55091
   PubMed Web of Science ®Google Scholar
• Mousavi M, Hellstrom-Lindahl E. Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. Neurochem Int 2009;54(3-4):237-44
   PubMed Web of Science ®Google Scholar
• EnVivo Pharmaceuticals, Inc. Safety, tolerability, pharmacokinetics of EVP-0962 and effects of EVP-0962 on cerebral spinal fluid amyloid concentrations in healthy subjects and in subjects with mild cognitive impairment or early Alzheimer's disease. Available from: www.clinicaltrials.gov/ct/show/NCT01661673 (Identifier: NCT01661673)
   Google Scholar
• Wallace TL, Callahan PM, Tehim A, et al. RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther 2011;336(1):242-53
   PubMed Web of Science ®Google Scholar
• Neugroschl J, Sano M. An update on treatment and prevention strategies for Alzheimer's disease. Curr Neurol Neurosci Rep 2009;9(5):368-76
   PubMed Web of Science ®Google Scholar
• Rocken C, Kintsch-Engel R, Mansfeld S, et al. Advanced glycation end products and receptor for advanced glycation endproducts in AA amyloidosis. Am J Pathol 2003;162:1213-20
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Agro A, Bell J, et al. PF-04494700, an oral inhibitor of receptor for advanced glycation endproducts (RAGE), in Alzheimer disease. Alzheimer Disease Assoc Disord 2011;25(3):206-12
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State” a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98
   PubMed Web of Science ®Google Scholar
• Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64
   PubMed Web of Science ®Google Scholar
• Galasko D, Bell J, Kupiec J, et al. A randomized clinical trial of. an inhibitor of RAGE-Abeta interactions in patients with mild to moderate AD. Presented at the 2011 Clinical Trials on Alzheimer's Disease meeting; 3 November 2011; San Diego, CA
   Google Scholar
• Hsiao K, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274(5284):99-102
   PubMed Web of Science ®Google Scholar
• Yan SD, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382(6593):685-91
   PubMed Web of Science ®Google Scholar
• Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012;122:1377-92
   PubMed Web of Science ®Google Scholar
• Craft S, Peskind E, Schwartz MW, et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998;50(1):164-8
   PubMed Web of Science ®Google Scholar
• De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 2009;106(6):1971-6
   PubMed Web of Science ®Google Scholar
• Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69(1):29-38
   PubMed Web of Science ®Google Scholar
• Hescham S, Lim LW, Jahanshahi A, et al. Deep brain stimulation in dementia-related disorders. Neurosci Biobehav Rev 2013;37(10 Pt 2):2666-75
   PubMed Web of Science ®Google Scholar
• Atamna H, Nguyen A, Schultz C, et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 2008;22(3):703-12
   PubMed Web of Science ®Google Scholar
• Mandel RJ. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther 2010;12(2):240-7
   PubMed Web of Science ®Google Scholar
• McClean PL, Parthsarathy V, Faivre E, Holscher H. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011;31(17):6587-94
   PubMed Web of Science ®Google Scholar
• Gerald Z, Ockert W. Alzheimer's disease market: hope deferred. Nat Rev Drug Discov 2013;12(1):19-20
   PubMed Web of Science ®Google Scholar
• Brunden KR, Zhang B, Carroll J, et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 2010;30(41):13861-6
   PubMed Web of Science ®Google Scholar
• Zhang B, Carroll J, Trojanowski JQ, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 2012;1432(11):3601-11
   Google Scholar
• Fukushima T, Makamura A, Iwakami N, et al. T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice. Biochem Biophys Res Commun 2011;407(4):730-4
   PubMed Web of Science ®Google Scholar
• Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol 2007;595:197-212
   PubMed Web of Science ®Google Scholar
• Faux NG, Ritchie CW, Gunn A, et al. PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J Alzheimers Dis 2010;20(2):509-16
   PubMed Web of Science ®Google Scholar
• Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double- blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9(4):363-72
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Ottonello S, Frisardi V, et al. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev Clin Immunol 2012;8(2):135-49
   PubMed Web of Science ®Google Scholar
• Goto T, Fujikoshi S, Uenaka K, et al. Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi- dose study. Alzheimers Dement 2012;6(Suppl 4):S308
   Google Scholar
• Thomas RG, Farlow M, Iwatsubo T, Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370(4):311-21
   PubMed Web of Science ®Google Scholar
• Dickenson DW. Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol 2009;3(1):1-23
   PubMedGoogle Scholar
• Magnoni S, Esparza TJ, Conte V, et al. Tau elevations in the brain of extracellular space correlated with reduced amyloid beta levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain 2011;135(4):1268-80
   PubMedGoogle Scholar
• Boutajangout A, Sigurdsson E, Krishnamurthy P. Tau as a therapeutic target for Alzheimer's disease. Curr Alzheimer Res 2011;8(6):666-77
   PubMed Web of Science ®Google Scholar
• Ibanez V, Pietrini P, Alexander GE, et al. Abnormal metabolic patterns in Alzheimer's disease after correction for partial volume effects. Neurology 1998;50:1585-93
   PubMed Web of Science ®Google Scholar
• Smith G, Laxton A, Tang-Wai D, et al. Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease. Arch Neurol 2012;69(9):1141-8
   PubMed Web of Science ®Google Scholar
• Berk C, Sabbagh M. Successes and failures for drugs in late-stage development for Alzheimer's disease. Drugs Aging 2013;30:783-92
   PubMed Web of Science ®Google Scholar